Innovation

Radio-Halogenated Flurobutenyl Tropanes for Imaging Dopamine Transporters

Emory University
posted on 07/07/2009

Applications

Imaging of dopamine transporters for drug development, research, diagnosis and treatment of CNS diseases and disorders such as Parkinson's disease and controlled substance addiction.

Highlights
  • Diagnostic imaging agents bind with high affinity to the dopamine transporter (DAT).
  • Useful for measuring neuronal function in the brain of patients suffering from various diseases and disorders of the CNS including major depression, obsessive compulsive disorder and drug addiction.
Technical Summary

Dopamine transporters are proteins that reside on the membrane of the nerve terminals of the presynaptic mesolimbic dopaminergic neurons. The DAT serves to remove dopamine from the synapse, a process which helps regulate CNS dopamine neurotransmission. DAT density level has been associated with Parkinson's disease. A radio-labeled analog that binds the dopamine transporter is an excellent candidate diagnostic radiopharmaceutical for diagnosis and treatment management of Parkinson's disease. It can also be used for treatment management of cocaine addiction.

The invention relates to a new series of brain imaging agents, N-(E)-4'-fluorobut-2-en-1-yl-2b-carbomethoxy -3b-(4-substituted-pheny) nortropane (FBNT). FBNT, when labeled with a positron emitting radioisotope such as 18F, can be used as a diagnostic imaging agent to measure central nervous system (CNS) neuronal function in the brain of patients suffering from Parkinson's disease and cocaine addiction. This tropane was designed to bind with high affinity to the dopamine transporter (DAT). FBCINT exhibits higher specific binding (i.e., greater than 12:1) striatal to cerebellum and striatal to cortex ratio in non-human primates) compared to any other reported PET DAT imagine agent. In addition, FBCINT reaches a transient equilibrium with DAT sites in the stratum which allows for quantitative determination of the number of DAT sites within a normal imaging session of 2 hours.

Product Development
  • Proof-of-principle has been demonstrated in a cell culture model as well as in vivo in a rat model.
]]>


Innovation Details
 

File Number: 99027 


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Cale Lennon at Emory University for more information.

Request more info via email request more info
People

Principal Investigator:

Mark Goodman Mark Goodman

Innovations (8)

Publications (7)



Co-Investigators:

Ping Chen Ping Chen

Innovations (2)

Case Manager:

Cale Lennon Cale Lennon

Innovations (19)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

7,868 members 17,196 innovations 152 organizations

Browse

Scott Steele, coordinator of the CTSA-IP initiative and director of research alliances at the University of Rochester

"With more than 3,700 innovations from CTSA member institutions already on the iBridge Network, we're garnering worldwide exposure for the breakthroughs our researchers are accomplishing while moving toward our goal of increasing human health through clinical and translational research."  read more...